(MedThink Communications) A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation.
The new vaccine used only half the standard antigen dose to produce this effect.The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.